Funds And Strategies
  • Business
  • Stocks
  • World News
  • Investing
  • Business
  • Stocks
  • World News
  • Investing

Funds And Strategies

Business

Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

by admin September 8, 2025
September 8, 2025
Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy

Shares of Kenvue fell more than 10% on Friday after a report that Health Secretary Robert F. Kennedy Jr. will likely link autism to the use of the company’s pain medication Tylenol in pregnant women.

HHS will release the report that could draw that link this month, The Wall Street Journal reported on Friday.

That report will also suggest a medicine derived from folate — a water-soluble vitamin — can be used to treat symptoms of the developmental disorder in some people, according to the Journal.

In a statement, an HHS spokesperson said, “We are using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates.”

“Until we release the final report, any claims about its contents are nothing more than speculation,” they added.

Tylenol could be the latest widely used and accepted treatment that Kennedy has undermined at the helm of HHS, which oversees federal health agencies that regulate drugs and other therapies. Kennedy has also taken steps to change vaccine policy in the U.S., and has amplified false claims about safe and effective shots that use mRNA technology.

Kennedy has made the disorder a key focus of HHS, pledging in April that the agency will “know what has caused the autism epidemic” by September and eliminate exposures. He also said that month that the agency has launched a “massive testing and research effort” involving hundreds of scientists worldwide that will determine the cause.

In a statement, Kenvue said it has “continuously evaluated the science and [continues] to believe there is no causal link” between the use of acetaminophen, the generic name for Tylenol, during pregnancy and autism.

The company added that the Food and Drug Administration and leading medical organizations “agree on the safety” of the drug, its use during pregnancy and the information provided on the Tylenol label.

The FDA website says the agency has not found “clear evidence” that appropriate use of acetaminophen during pregnancy causes “adverse pregnancy, birth, neurobehavioral, or developmental outcomes.” But the FDA said it advises pregnant women to speak with their health-care providers before using over-the-counter drugs.

The American College of Obstetricians and Gynecologists maintains that acetaminophen is safe during pregnancy when taken as directed and after consulting a health-care provider.

Some previous studies have suggested the drug poses risks to fetal development, and some parents have brought lawsuits claiming that they gave birth to children with autism after using it.

But a federal judge in Manhattan ruled in 2023 that some of those lawsuits lacked scientific evidence and later ended the litigation in 2024. Some research has also found no association between acetaminophen use and autism.

In a note on Friday, BNP Paribas analyst Navann Ty said the firm believes the “hurdle to proving causation [between the drug and autism] is high, particularly given that the litigation previously concluded in Kenvue’s favor.”

This post appeared first on NBC NEWS

previous post
CORRECTED: CHARBONE Hydrogen is Acquiring Hydrogen Production Assets and Closing a First Tranche of $1M Private Placement Financing
next post
Reinstatement to Official Quotation

Related Posts

White House accuses Powell of mismanaging Federal Reserve,...

July 11, 2025

‘He’s like Iron Man’: Jensen Huang lit up...

June 11, 2025

Uber delivery chief Gore-Coty is leaving after almost...

June 4, 2025

JPMorgan marks 1,000th branch opening since 2018 expansion...

August 2, 2025

Home Depot is buying GMS for about $4.3...

July 1, 2025

Consumers are not lovin’ it: McDonald’s has its...

May 2, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (223)
    • Investing (985)
    • Stocks (206)
    • World News (648)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 fundsandstrategies.com | All Rights Reserved